NLS Pharmaceutics Return on Equity

NLS Pharmaceutics (NLSP) currently reports a ROE of -303.93%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore NLS Pharmaceutics's ROE history and peer comparisons.

NLS Pharmaceutics's ROE of -303.93% is lower than the Healthcare sector average of 21.67%. That is roughly 1502.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NLS Pharmaceutics's current -303.93% should be judged against Healthcare norms (sector average: 21.67%) and against NLSP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -303.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for NLS Pharmaceutics, and consider following NLSP for alerts when major investors trade the stock.

NLS Pharmaceutics is classified in the Healthcare sector. On ROE, it currently shows -303.93% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NLSP with unrelated industries.